XenoPort, Inc.

FDA is again being pulled into the drug pricing debate, this time by insurance companies with a report suggests that drugmakers may be exploiting orphan drug designation for economic gain with the non

Nathalie Moll, currently secretary general of the European Association for Bioindustries,has been appointed EFPIA's director general – effective April, 2017. Eric Cornut will continue to lead EFPI

The Pink Sheet regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between May 21-June

IN VITRO DIAGNOSTICS Mergers & Acquisitions Luminex Corp. Nanosphere Inc. Luminex Corp. is paying $77mm ($1.70 per share; a 63% premium) in cash to acquire molecular diagnostics firm Nanosphere